Canaccord Genuity Reiterates Buy Rating on Intellia Therapeutics
Canaccord Genuity maintains a positive outlook on Intellia Therapeutics with a $49 target.
Key Points
- Canaccord Genuity reiterated its buy rating on Intellia Therapeutics, setting a $49 price target on June 16, 2026.
- Intellia Therapeutics, a biotechnology company, has a market cap of about $2.08 billion and a negative forward P/E due to lack of profitability.
- Key insiders, including Fred Cohen and William Chase, bought shares in early June, reflecting confidence in the company's prospects.
Canaccord Genuity has reaffirmed its buy rating on Intellia Therapeutics, Inc. (NasdaqGM: NTLA) with a price target of $49. This rating was reiterated by analyst Whitney Ijem on June 16, 2026. The stock was recently trading at $14.92.
Intellia Therapeutics Stock Snapshot
Shares of NasdaqGM:NTLA traded near $14.92. Intellia Therapeutics has a market cap of approximately $2.08 billion and a beta of 1.815, indicating higher volatility compared to the market. The stock's 52-week range is between $7.95 and $28.25, with a 50-day moving average of $13.66 and a 200-day moving average of $13.41. The company has a strong current ratio of 6.10, suggesting good short-term financial health, and a quick ratio of 5.04.
Recent Earnings
In its latest earnings report, Intellia Therapeutics recorded revenue of $66.1 million, though it faced a revenue decline of 9.5%. The company is not currently profitable, with a negative return on equity of -56.3%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Intellia Therapeutics, Inc.
Several insiders at Intellia Therapeutics made notable purchases on June 9, 2026. Fred Cohen, William Chase, and Georgia Keresty each acquired 13,300 shares, while Brian Goff and Muna Bhanji purchased 9,200 shares each. These transactions were not part of a pre-planned trading program, indicating direct insider confidence in the company's future.
Analysts Set New Price Targets
On June 16, 2026, Canaccord Genuity maintained its buy rating for Intellia Therapeutics with a $49 price target. Previously, on June 15, Citizens reiterated a buy rating with a $30 target, and Wedbush reiterated a hold rating with a $12 target. The consensus among 19 analysts is a buy rating, with an average target price of $26.63.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. It focuses on developing treatments using CRISPR/Cas9 genome editing technology. The company is working on therapies for transthyretin amyloidosis, hereditary angioedema, and other diseases. Led by CEO Dr. John M. Leonard, Intellia collaborates with several partners to advance gene editing applications.
Bottom Line
Canaccord Genuity's reaffirmation of a buy rating and a $49 target for Intellia Therapeutics highlights continued confidence in the company's potential. Investors often track analyst ratings as they can influence stock movements. It's important to remember that analyst ratings are forward-looking assessments and may not reflect current market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.